# To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

> **NCT02093728** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 26 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** selumetinib
- **DRUG:** itraconazole
- **DRUG:** itraconazole
- **DRUG:** selumetinib
- **DRUG:** selumetinib
- **DRUG:** fluconazole
- **DRUG:** fluconazole
- **DRUG:** selumetinib

## Key facts

- **NCT ID:** NCT02093728
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02093728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02093728, "To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02093728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*